PSIVIDA Limited’s UK subsidiary pSiMedica has signed a research materials agreement with EpiTan Limited.
Under the agreement EpiTan will evaluate the use of BioSilicon as a delivery platform for some of the products it has under development.
EpiTan aims to develop a new liquid-based sustained-release formulation with initial proof of concept studies expected to be complete by the end of this year.
It has the exclusive worldwide rights to develop Melanotan, which early results from Phase IIb clinical trials has shown to increase the concentration of melanin in the skin and, in doing so, has the potential to reduce the incidence of skin damage.
pSivida managing director Gavin Revos said BioSilicon provided flexibility in delivery methods and would be an ideal method for EpiTan’s Melanotan.